a b s t r a c t
This data contain left ventricular end-diastolic volumes, end-systolic volumes, stroke volumes, ejection fractions, cardiac outputs, heart rates, phosphocreatine concentrations, adenosine 5'-triphosphate (ATP) concentrations, total creatine concentrations, citrate synthase activities and heart weights for wild-type and peroxisome proliferator-activated receptor-alpha-null mouse hearts without and with triiodothyronine treatment. 
Value of the Data
The data can be used to further investigate whether the cross-talk between peroxisome proliferator-activated receptor-alpha and triiodothyronine signaling pathways in vitro happens in hearts in vivo.
The data can be used to investigate how peroxisome proliferator-activated receptor-alpha and triiodothyronine regulate mitochondrial contents in hearts.
The data can be used to investigate the role of peroxisome proliferator-activated receptor-alpha in left ventricular dysfunction in human non-alcoholic fatty liver disease and in pharmaceutical area.
Data
Triiodothyronine treatment causes abnormal decrease of left ventricular stroke volumes, phosphocreatine concentrations and ATP concentrations associated with abnormal increase of heart weights and citrate synthase activities in peroxisome proliferator-activated receptor-alpha-null mouse hearts (Fig. 1) .
Experimental design, materials, and methods
Cardiac magnetic resonance imaging, magnetic resonance spectroscopy, total creatine concentrations and citrate synthase activities as previously described [1] were quantified in male wild-type (129S6/SvEv) (n ¼ 12), age-matched male peroxisome proliferator-activated receptor-alpha-null mice (129/Sv strain background) (n ¼ 12), age-matched triiodothyronine-injected male wild-type (n ¼ 15) and age-matched triiodothyronine-injected male peroxisome proliferator-activated receptor-alpha-null mice (n ¼ 13) at the age of 8 months old. All the procedures were approved by the Animal Ethics Review Committees, University of Oxford, and by the Home Office, United Kingdom. Triiodothyronine-injected wild-type and peroxisome proliferator-activated receptor-alpha-null mice were injected 3,3',5-triiodo-L-thyronine solution (0.2 mg per kg body weight per day) for 7 consecutive days intraperitoneally. Differences between two groups were analyzed by Student's t-test. Fig. 1 . Magnetic resonance imaging and spectroscopy data. A: Representative images at end-diastole. Scale bar ¼ 2 mm. PPARα-null, peroxisome proliferator-activated receptor-alpha-null; T3,triiodothyronine. B: Quantified magnetic resonance imaging data (n ¼ 6 for wild-type, n ¼ 6 for PPARα-null, n ¼ 8 for T3-treated wild-type, and n ¼ 6 for T3-treated PPARα-null). LV EDV, left ventricular end-diastolic volume; ESV, end-systolic volume; SV, stroke volume; EF, ejection fraction; CO, cardiac output. Stroke volume ¼ end-diastolic volume -end-systolic volume; ejection fraction ¼ stroke volume/end-diastolic volume; cardiac output ¼ stroke volume x heart rate. C: Representative spectra. Pi, inorganic phosphate; PCr, phosphocreatine; γ, α and β ATP, γ, α and β phosphate groups of adenosine-5'-triphosphate. D: Quantified magnetic resonance spectroscopy, total creatine, and citrate synthase activities data (n ¼ 6 for wild-type, n ¼ 6 for PPARα-null, n ¼ 7 for T3-treated wild-type, and n ¼ 7 for T3-treated PPARα-null). ΔG ATP , free energy available from ATP hydrolysis; gww, gram wet weight. Data are means 7 SEM. * P o 0.05 vs. wild-type; † P o 0.01 vs. wild-type; ‡ P o 0.05 vs. T3-treated wild-type; § P o 0.01 vs. T3-treated wild-type, ǁ P o 0.05 vs. PPARα-null, # P o 0.01 vs. PPARα-null.
Acknowledgments
Wen Zhang acknowledges Clarendon Scholarships from University of Oxford and Hong Kong Oxford Scholarship for supporting her DPhil studies.
Funding resources
This work is part of Wen Zhang's DPhil thesis and was supported by the British Heart Foundation (grant reference PG/07/030/22667).
Transparency document. Supporting information
Transparency data associated with this article can be found in the online version at https://doi.org/ 10.1016/j.dib.2018.08.009.
